Xenon Pharmaceuticals (XENE) Non-Current Assets (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Non-Current Assets of $280.2 million for Q1 2026, up 57.63% year-over-year from $177.7 million in Q1 2025, and up 286.38% quarter-over-quarter from $72.5 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Non-Current Assets (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Non-Current Assets for 14 consecutive years, with $280.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 57.63% year-over-year to $280.2 million; the TTM figure through Mar 2026 stood at $654.4 million (down 2.73% YoY), while the FY2025 annual figure was $72.5 million, down 55.48% from the prior year.
- Non-Current Assets grew to $280.2 million in Q1 2026 per XENE's latest filing, from $72.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $319.8 million in Q4 2023 and bottomed at $12.4 million in Q1 2022.
- Historically, Non-Current Assets has averaged $154.8 million across 5 years, with a median of $155.9 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 1475.28% — and 2025, when it slumped 55.48%.
- Xenon Pharmaceuticals' Non-Current Assets stood at $153.8 million in 2022, then surged by 107.89% to $319.8 million in 2023, then slumped by 49.08% to $162.9 million in 2024, then slumped by 55.48% to $72.5 million in 2025, then jumped by 286.38% to $280.2 million in 2026.
- Business Quant data shows XENE's Non-Current Assets at $280.2 million in Q1 2026, $72.5 million in Q4 2025, and $127.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 349.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 349.90 Mn |
| Mar 31, 2026 | 280.18 Mn |
| Dec 31, 2025 | 72.51 Mn |
| Sep 30, 2025 | 127.70 Mn |
| Jun 30, 2025 | 174.03 Mn |
| Mar 31, 2025 | 177.74 Mn |
| Dec 31, 2024 | 162.88 Mn |
| Sep 30, 2024 | 176.26 Mn |
| Jun 30, 2024 | 155.92 Mn |
| Mar 31, 2024 | 211.82 Mn |
| Dec 31, 2023 | 319.84 Mn |
| Sep 30, 2023 | 140.09 Mn |
| Jun 30, 2023 | 140.28 Mn |
| Mar 31, 2023 | 186.52 Mn |
| Dec 31, 2022 | 153.85 Mn |
| Sep 30, 2022 | 126.64 Mn |
| Jun 30, 2022 | 12.58 Mn |
| Mar 31, 2022 | 12.44 Mn |
| Dec 31, 2021 | 12.99 Mn |
| Sep 30, 2021 | 8.04 Mn |